Sheffield CiC 2016: Addressing the funding gap to advance early stage healthcare research in Sheffield

Lead Research Organisation: University of Sheffield
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

People

ORCID iD
 
Description Innovation and Knowledge Centre Proof of Concept
Amount £100,000 (GBP)
Organisation Versus Arthritis 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2018 
End 10/2019
 
Title ANTIMICROBIAL COATING 
Description IP for project technology 
IP Reference EP2328627 
Protection Patent granted
Year Protection Granted 2011
Licensed Commercial In Confidence
Impact too early
 
Title APPARATUS AND METHOD FOR EVALUATING BIOLOGICAL TISSUE 
Description An electrical impedance spectroscopy (EIS) system for the detection of tissue abnormalities of muscle, for example, because of neuromuscular disorders such as amyotrophic lateral sclerosis (ALS). In particular, a EIS probe is disclosed having a three dimensional array of electrodes separated from one another in the x, y and z coordinates by quantitative separation distances. 
IP Reference WO2018206964 
Protection Patent granted
Year Protection Granted 2018
Licensed Commercial In Confidence
Impact Commercial In Confidence
 
Title LOW DOSE ASPIRIN (1-50 MG) TOGETHER WITH ANTIPLATELETS SUCH AS TICAGRELOR OF ANTICOAGULANTS 
Description The present disclosure concerns a dosage regimen consisting of ultra-low doses of irreversible cyclooxygenase inhibitors in combination with platelet aggregation inhibitors or anticoagulant agents for the prevention and treatment of acute coronary syndromes and other ischaemic events. 
IP Reference WO2018167447 
Protection Patent granted
Year Protection Granted 2018
Licensed Commercial In Confidence
Impact Commercial In Confidence
 
Title NEUROTOXINS 
Description The present invention provides neurotoxins comprising a SNARE peptidase domain, a translocation domain, a first Neuronal binding domain (Nbd) and a second Neuronal binding domain (Nbd). The invention also provides compositions (e.g. pharmaceutical compositions) comprising said neurotoxins, and uses thereof. 
IP Reference WO2018109447 
Protection Patent granted
Year Protection Granted 2018
Licensed Commercial In Confidence
Impact Commercial In Confidence
 
Title PARATHYROID HORMONE FUSION POLYPEPTIDE 
Description The disclosure relates to long acting parathyroid or parathyroid hormone like fusion polypeptides comprising a receptor polypeptide and its use in the treatment of hypoparathyroidism and osteoporosis. 
IP Reference WO2018197895 
Protection Patent granted
Year Protection Granted 2018
Licensed Commercial In Confidence
Impact Commercial In Confidence